logo

For the Inventor, By the Inventor

New City, NY, United States of America

Jeremy Ian Levin

This inventor holds 60 USPTO granted patents and 2 published patent applications, primarily in Matrix Metalloproteinase Inhibitors (CPC class 5142). Top assignees: American Cyanamid Company, Wyeth Holdings Corporation, Wyeth. Active years: 1988-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremy Ian Levin. Retrieved from https://idiyas.com/inventor/jeremy-ian-levin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 60 

% Patents Active = 75.0

Average Co-Inventor Count = 2.4

ph-index = 13

Forward Citations = 374(Granted Patents)

Forward Citations (Not Self Cited) = 326(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Rockland, NY (US) (1992)
  • Spring Valley, NY (US) (1988 - 1995)
  • Nannet, NY (US) (1998 - 2000)
  • Nanuet, NY (US) (1994 - 2003)
  • New City, NY (US) (2001 - 2009)

Company Filing History:

goldMedal42 out of 3,580 
 
American Cyanamid Company
 patents
silverMedal8 out of 113 
 
Wyeth Holdings Corporation
 patents
bronzeMedal6 out of 1,309 
 
Wyeth
 patents
4. 3 out of 1,567 
 
American Home Products Corporation
 patents
5. 1 out of 451 
 
Immunex Corporation
 patents
6. 1 out of 1 
 
Max-Planck-Institute for Biochemistry
 patent
7. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1988-2009

Loading Chart...
Areas of Expertise:
Matrix Metalloproteinase
TACE Inhibitors
Hydroxamic Acids
Sulfonamides
Bicyclic Compounds
Acetylenic Derivatives
Alkyl Amides
Phosphinic Acids
Biaryl Structures
Polycystic Kidney Disease
Neutropenia Treatment
Crystalline Enzymes
60 patents (USPTO):Explore Patents
1. 7595327 - Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase (2009-09-29),
2. 7576222 - Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase (2009-08-18),
3. 7488754 - Method for the treatment of polycystic kidney disease (2009-02-10),
4. 7485667 - Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors (2009-02-03),
5. 7420001 - Biaryl sulfonamides and methods for using same (2008-09-02),
6. 7199155 - Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors (2007-04-03),
7. 7179911 - Method for preparing hydroxamic acids (2007-02-20),
8. 6946473 - Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors (2005-09-20),
9. 6842704 - Crystalline TNF-α-converting enzyme and uses thereof (2005-01-11),
10. 6825354 - Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors (2004-11-30),
11. 6812227 - Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors (2004-11-02),
12. 6762178 - Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors (2004-07-13),
13. 6753337 - Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors (2004-06-22),
14. 6716833 - Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors (2004-04-06),
15. 6548524 - Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors (2003-04-15),

Title: **The Innovative Contributions of Jeremy Ian Levin**

Introduction

Jeremy Ian Levin, based in New City, NY, is a distinguished inventor known for his impressive portfolio of 60 patents. His innovative work primarily focuses on the development of therapeutic compounds, particularly in the realm of treating diseases associated with TNF-α.

Latest Patents

Among his notable inventions are two recent patents:

1. **Beta-sulfonamide Hydroxamic Acid Inhibitors of TACE/Matrix Metalloproteinase**

This invention encompasses compounds that are effective in treating various diseases and disorders mediated by TNF-α. These conditions include rheumatoid arthritis, tumor metastasis, tissue ulceration, diabetes, multiple sclerosis, and many others. The invention not only details the structural compounds but also outlines methods for their use in alleviating symptoms associated with these conditions.

2. **Alkynyl-Containing Tryptophan Derivative Inhibitors of TACE/Matrix Metalloproteinase**

This invention presents compounds similarly aimed at addressing diseases mediated by TNF-α, providing methods for use in treatment and symptom alleviation.

Career Highlights

Jeremy has made significant contributions while working with renowned companies, including American Cyanamid Company and Wyeth Holdings Corporation. His career has been marked by a commitment to innovation, consistently pushing the boundaries of medical research and therapeutic development.

Collaborations

Throughout his career, Jeremy has collaborated with esteemed professionals, including Aranapakam Mudumbai Venkatesan and James Ming Chen. These partnerships have undoubtedly enhanced the innovative capacity of his projects, fostering an environment of collaborative research and development.

Conclusion

In summary, Jeremy Ian Levin stands out as a prominent inventor whose contributions through his extensive patent portfolio demonstrate the vital intersection of innovation and medicine. His dedication to addressing complex health issues continues to inspire advancements in therapeutic treatments and showcases the profound impact of inventive ingenuity in the healthcare field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…